Factors Associated With Newborn Nirsevimab Administration in Los Angeles County During the 2024 Respiratory Syncytial Virus Season
Nirsevimab reduces respiratory syncytial virus-related hospitalizations and is recommended for infants shortly after birth during RSV season. We compared characteristics of newborns who received nirsevimab to those who received hepatitis B vaccine within one week of life to better identify gaps in coverage and target public health outreach. One year after the introduction of nirsevimab, fewer infants received the recommended birth dose of nirsevimab as compared to hepatitis B vaccine.
Authors
- Megan Halbrook (ORCID: https://orcid.org/0000-0002-3892-2655)
- Nava Yeganeh (ORCID: https://orcid.org/0000-0002-4695-1464)
- Sherry Yin
- James Beekley
- Mollie Barr
- Huan Vinh Dong (ORCID: https://orcid.org/0000-0002-6370-1811)
- Neema Pithia (ORCID: https://orcid.org/0000-0002-6314-6547)
- Adriana Graciela Díaz (ORCID: https://orcid.org/0000-0002-9108-2288)
- Chih‐Long Chiang
Institutions
- Los Angeles County Department of Public Health (US)
- University of California, Los Angeles (US)
- Los Angeles Medical Center (US)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1093/jpids/piaf095
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00